Enliven Therapeutics Inc Quick Ratio (ELVN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Enliven Therapeutics Inc   (NASDAQ: ELVN)

Enliven Therapeutics Inc 's Quick Ratio

ELVN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 45.41 below Enliven Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Enliven Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 17 to 42.

Explain Quick Ratio?
How much Cash & cash equivalents ELVN´s has?
What are ELVN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ELVN/financial-strength
https://api.csimarket.com/api/v1/companies/ELVN/fundamentals
https://api.csimarket.com/api/v1/companies/ELVN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ELVN Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 1262.7 %
Y / Y Cash & cash equivalent Change 85.18 %
Quick Ratio MRQ 45.41
ELVN's Total Ranking # 42
Seq. Current Liabilities Change 37.51 %
Seq. Cash & cash equivalent Change -46.56 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 4
Overall Market # 42


Quick Ratio Statistics
High Average Low
334.2 78.64 0
(Sep 30 2025)   (Sep 30 2012)




Financial Statements
Enliven Therapeutics Inc 's Current Liabilities $ 19 Millions Visit ELVN's Balance sheet
Enliven Therapeutics Inc 's Cash & cash equivalent $ 884 Millions Visit ELVN's Balance sheet
Source of ELVN's Sales Visit ELVN's Sales by Geography


Cumulative Enliven Therapeutics Inc 's Quick Ratio

ELVN's Quick Ratio for the trailling 12 Months

ELVN Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 460.04 %
Y / Y Cash & cash equivalent TTM Growth 119.87 %
Quick Ratio TTM 92.28
Total Ranking TTM # 179
Seq. Current Liabilities TTM Growth 93.06 %
Seq. Cash & cash equivalent TTM Growth 13.35 %

Quick ratio ranking by company, industry and sector >> Back to ELVN Financial Strength Comparisons >> Go to Compare ELVN Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $19.47 millions, cumulative Quick Ratio decreased to 92.28 above the ELVN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 400 other companies have achieved higher Quick Ratio than Enliven Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 1999 to 2758.

Explain Quick Ratio?
How much Cash & cash equivalents ELVN´s has?
What are ELVN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 401
Healthcare Sector # 785
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
21.59 10.87 0.01
(Jun 30 2026)   (Sep 30 2012)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Altimmune inc   101.51 $ 1,170.025  Millions$ 11.526  Millions
Vogenx, Inc.  97.47 $ 82.118  Millions$ 0.842  Millions
Veradermics Inc  89.45 $ 927.861  Millions$ 10.373  Millions
Arca Biopharma Inc  83.92 $ 1,206.587  Millions$ 14.377  Millions
Incannex Healthcare Inc  65.89 $ 68.267  Millions$ 1.036  Millions
Monopar Therapeutics Inc   61.05 $ 182.056  Millions$ 2.982  Millions
Q32 Bio Inc   56.05 $ 289.587  Millions$ 5.167  Millions
Rallybio Corporation  51.94 $ 90.693  Millions$ 1.746  Millions
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Fulcrum Therapeutics Inc   35.70 $ 306.545  Millions$ 8.587  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Avalyn Pharma Inc   32.64 $ 422.814  Millions$ 12.955  Millions
Immix Biopharma Inc   30.89 $ 336.303  Millions$ 10.889  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions

Date modified: 2026-11-08T19:19:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.